cas 1151802-23-1|| where to buy 4-Bromo-1-cyclopropyl-1H-pyrazole

製品名:4-Bromo-1-cyclopropyl-1H-pyrazole

IUPAC Name:4-bromo-1-cyclopropyl-1H-pyrazole

包装単位	有効在庫	価格（USD）
CM187743-1g	in stock	Ůƚ
CM187743-5g	in stock	ħǸǸ
CM187743-10g	in stock	ǸƚǙ
CM187743-25g	in stock	ŮǪƚ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1151802-23-1 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:1151802-23-1; 分子式:C6H7BrN2; 融点:-; SMILESコード:BrC1=CN(N=C1)C1CC1; 密度:

: カタログ番号:CM187743; 分子量:187.04; 沸点:; MDL番号:MFCD18250639; 保管方法:Store at 2-8°C.

: Pyrazoles; Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.; Pyrazone; Custom pyrazone for customers from all over the world are our main business.

: Cyclopropanes; Cyclopropane is the smallest cyclic compound with unique structural features and physicochemical properties, which is widely used in the design of small molecule drugs. In drug design, it is often used to increase activity, fix conformation and improve PK and water solubility. The introduction of cyclopropyl groups into drugs can change various properties of molecules, such as improving metabolic stability; increasing biological activity; enhancing drug efficacy; limiting polypeptide conformation and slowing down its hydrolysis; reducing plasma clearance; improving drug dissociation and many more. Cyclopropane rings are widely found in marketed drugs, including cardiovascular drugs, central nervous system (CNS) drugs, anticancer drugs, autoimmune and anti-inflammatory drugs.

: Vebreltinib; Avistone announced that they received conditional approval from the National Medical Products Administration (NMPA) to commercialize Vebreltinib (Bozitinib) to treat patients with MET exon 14 skipping non-small cell lung cancer (NSCLC) in China. The conditional approval was based on results from a pivotal Phase II KUNPENG study with an objective response rate (ORR) of 75.0% and median progression-free survival (PFS) in patients with advanced METex14 mutations to 14.1 months with a good safety profile as was recently presented at the 2023 European Society for Clinical Oncology (ESMO) Congress in Madrid, Spain. Vebreltinib is a potent, small molecule, orally bioavailable and highly selective c-Met Tyrosine Kinase Inhibitor (TKI).
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.